Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a Healthcare company (Medical - Devices) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
Tandem Diabetes Care, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.06, Tandem Diabetes Care, Inc. trades at 1.1x sales and 8.9x book value. Over the last twelve months it generated about $1.1B of revenue and a net loss of $50M. It runs a gross margin of 56.6%, an operating margin of -2.4% and a net margin of -4.6%. It shows return on equity of -35.6%, return on invested capital of -2.7% and a free cash flow yield of -3.0%. On the balance sheet: a debt-to-equity ratio of 5.45 and a current ratio of 3.21. Over the past 52 weeks the share price ranged from $12.26 to $29.65, with a beta of 1.59.
Tandem Diabetes Care, Inc. does not currently pay a dividend.
39 Wall Street analyst ratings cover the stock: 23 Buy and 16 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Tandem Diabetes Care, Inc. (TNDM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 47.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 45.1% / 30% · Interest income / Revenue 1.31% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 47.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 35.2% / 33% · Receivables / Mkt Cap (36m) 14.3% / 49% · Interest income / Revenue 1.31% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 47.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 35.2% / 33.33% · Receivables / Mkt Cap (24m) 14.3% / 33.33% · Interest income / Revenue 1.31% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 51.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 40.5% / 33.33% · Receivables / Avg Assets (4Q) 14.9% / 33.33% · Interest income / Revenue 1.31% / 5% | Fail |
| FTSE | Debt / Total Assets 52.0% / 33.33% · (Cash+ST Inv) / Total Assets 38.2% / 33.33% · (Cash+Recv) / Total Assets 53.7% / 33.33% · Interest income / Revenue 1.31% / 5% | Fail |
No. As of September 2026, Tandem Diabetes Care, Inc. (TNDM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Tandem Diabetes Care, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 1.31% of each dividend: Tandem Diabetes Care, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.